H1B Report
Side-by-side comparison

ASCENT PHARMACEUTICALS, INC. vs Deloitte Consulting LLP

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
ASCENT PHARMACEUTICALS, INC.
NYRank #FEIN 45-3542806
Entity B
Deloitte Consulting LLP
PARank #4FEIN 06-1454513

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricASCENT PHARMACEUTICALS, INC.Deloitte Consulting LLP
Total filings24380,813
Certified %98.77%98.23%
Denied %0.41%1.09%
Withdrawn %0.82%0.61%
Cert-withdrawn %0.00%0.07%
Rank#4
Active yearsFY2011–FY2026FY2010–FY2026
Worksite stateNYPA

Outcomes — ASCENT PHARMACEUTICALS, INC.

DOL case-status mix.

Outcome breakdown: Certified 98.8%, Withdrawn 0.8%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified98.8%
Withdrawn0.8%
Denied0.4%
Certified98.8%
Withdrawn0.8%
Denied0.4%

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

ASCENT PHARMACEUTICALS, INC.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20100
FY20112
FY20120
FY201315
FY201422
FY201511
FY201624
FY201757
FY201823
FY201936
FY20200
FY20210
FY20220
FY20230
FY202413
FY202526
FY202614
Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612

Top 5 occupations — ASCENT PHARMACEUTICALS, INC.

Top 5 occupations — Deloitte Consulting LLP

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.